## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.04 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-7.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($239.03)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. OIG Audit of Humana Medicare Advantage Contract Underscores Continued Scrutiny of High-Risk Diagnoses and Ongoing Disputes Over Audit Methodology**
- Source: WilmerHale | 20251223T175358 | Somewhat-Bearish | Relevance: 100%
- The OIG audit of a Humana Medicare Advantage contract highlights ongoing regulatory focus on "high-risk" diagnosis codes, leading to disputes over audit methodology, particularly regarding extrapolation and credit for underpayments. The article discusses Humana's objections to the audit findings and the broader implications for Medicare Advantage Organizations (MAOs) amidst evolving litigation and regulatory scrutiny. MAOs are advised to diligently preserve objections during audits to facilitate potential future litigation.

**2. Thrivent Financial for Lutherans Sells 236,009 Shares of Humana Inc. $HUM**
- Source: MarketBeat | 20251221T100805 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly reduced its stake in Humana Inc. by selling 236,009 shares, cutting its holdings by 93.2%. Despite this, other major institutions like Vanguard, Dodge & Cox, and State Street largely increased their positions, resulting in institutional investors and hedge funds owning 92.38% of Humana's stock. Humana reported strong Q3 earnings, exceeding analyst expectations, and declared a quarterly dividend of $0.885.

**3. Humana Inc. (NYSE:HUM) Given Average Recommendation of "Hold" by Analysts**
- Source: MarketBeat | 20251221T080801 | Neutral | Relevance: 100%
- Analysts have given Humana Inc. (NYSE:HUM) an average "Hold" rating, based on recommendations from twenty-one analysts with an average 12-month price target of $294.32, suggesting a 13% upside from Friday's opening price. The company surpassed Q3 earnings estimates with EPS of $3.24 and saw revenue increase by 11.1% year-over-year to $32.65 billion, also declaring a quarterly dividend of $0.885. Institutional investors hold a significant portion of the stock, while several research analysts recently adjusted their ratings and price targets for Humana.

**4. Behind the reported Humana Building deal (Access Louisville Podcast)**
- Source: The Business Journals | 20251222T115606 | Neutral | Relevance: 100%
- LBF Senior Reporter Joel Stinnett discusses the potential sale of the Humana Building, located at 500 W. Main Street, to be redeveloped as a large hotel. He shares insights into gathering sources for this developing story on the "Access Louisville" podcast. This deal is reportedly being finalized behind the scenes, potentially changing a significant downtown Louisville landmark.

**5. Texas Permanent School Fund Corp Sells 13,598 Shares of Humana Inc. $HUM**
- Source: MarketBeat | 20251222T100753 | Neutral | Relevance: 99%
- Texas Permanent School Fund Corp reduced its stake in Humana Inc. by 59.3%, selling 13,598 shares and retaining 9,345 shares worth approximately $2.285 million. Other institutional investors also adjusted their holdings in Humana. The company reported strong quarterly earnings, beating analyst estimates, and has a "Hold" consensus rating from analysts with an average price target of $294.32.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Morgan Stanley | $262 | $277 | -5% |
| 2025-12-05 | Jefferies | $313 | $253 | +24% |
| 2025-11-25 | Barclays | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-12-05 | Jefferies | up | Buy |
| 2025-11-25 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.14M) |
| Sells | 6 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.04 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Analyst sentiment negative (2 target cuts vs 1 raises). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $30.9B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.04 |
| Forward P/E | 20.7 |
| Current P/E | 15.1 |
| YoY Growth | -27.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.6% to -0.3% (-7.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. MACD histogram positive (0.62), confirming momentum. RSI neutral at 51. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.34% (CS: 52) | Neutral |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | 0.62 | Bullish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 0.994x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $257.13
- **Stop Loss:** $239.03 (7.0% risk)
- **Target:** $293.33 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 66
- **Position Value:** $16,970.58
- **Portfolio %:** 16.97%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*